<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Issuer
Pursuant to Rule 424[b][3] of
The Securities Exchange Act of 1934
Prospectus Supplement dated August 18,2000
Nymox Pharmaceutical Corporation
9900 Cavendish Blvd., St. Laurent, QC, Canada, H4M 2V2
(Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20F or Form 40F)
Form 20 F [X] Form 40 F [ ]
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934)
Yes [ ] No [X]
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
NYMOX PHARMACEUTICAL CORPORATION
(Registrant)
Date: August 18, 2000 /s/ Paul Averback
------------------------------------------
Paul Averback, MD - President
<PAGE> 2
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-31310
NYMOX PHARMACEUTICAL CORPORATION
Prospectus Supplement
(To Prospectus Dated March 9, 2000)
You should read this prospectus supplement and the related prospectus
carefully before you invest. Both documents contain information you should
consider when making your investment decision.
On July 17, 2000, we issued a drawdown notice to Jaspas Investments Limited
in connection with the common stock purchase agreement dated November 1, 1999,
evidencing an equity draw down facility between us and Jaspas Investments
Limited. This notice offered to sell up to $12,000,000 of our common stock to
Jaspas Investments Limited based on the formula in the stock purchase agreement,
during the 22 day period beginning on July 17, 2000 and ending on August 15,
2000, but at not less than $3.00 per share. During the 22 days, Jaspas
Investments Limited purchased a total of 152,616 shares of our common stock at
an average purchase price of $3.3041 per share. These purchases resulted in
aggregate proceeds of $500,000 being paid and released from escrow to us by
Jaspas Investments Limited. Ladenburg Thalmann & Co. Inc. received $15,000 as a
placement fee in connection with this drawdown.
The attached prospectus relates to the resale of shares acquired by Jaspas
Investments Limited pursuant to the stock purchase agreement. Because Jaspas
Investments may sell some or all of these shares, and because there are
currently no agreements, arrangements or understandings with respect to the sale
of any of these shares, we cannot estimate the actual amount of shares that they
will hold after the completion of the offering. We expect to use the proceeds of
this common stock for general operating purposes.
THE DATE OF THIS PROSPECTUS SUPPLEMENT IS AUGUST 18, 2000.
